Details of the Drug Excipient

General Information of Drug Inactive Ingredient (DIG) (ID: E00522)

• DIG Name: Ferric oxide black
• Synonyms: Iron(II,III)oxide; Iron Oxide Black; Fe3O4; 12227-89-3; Iron(II,III) oxide, CP; oxoiron;oxo(oxoferriooxy)iron; IRON PIGMENT BLACK (E172); S350; Iron(II,III) oxide, powder, <5 mum, 95%; Iron(II,III) oxide, 99.99% trace metals basis; Q411235; Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in H2O; Iron(II,III) oxide, nanopowder, 50-100 nm particle size (SEM), 97% trace metals basis; 120899-48-1; Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), carboxylic acid functionalized, 5 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in H2O; Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in toluene; Iron oxide(II,III), magnetic nanoparticles solution, 10 nm diameter, biotin functionalized, 1 mg/mL Fe, dispersion in H2O; Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in H2O; Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in toluene; Iron oxide(II,III), magnetic nanoparticles solution, 30 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 30 nm avg. part. size (TEM), PEG functionalized, dispersion, 1 mg/mL Fe in H2O; Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), amine functionalized, 1 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), biotin functionalized, 1 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size (TEM), PEG functionalized, 1 mg/mL Fe in H2O, dispersion; Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in toluene
• DIG Function: Colorant
• Formula: Fe3O4
• Canonical SMILES: O=[Fe].O=[Fe]O[Fe]=O
• InChI: 1S/3Fe.4O
• InChIKey: SZVJSHCCFOBDDC-UHFFFAOYSA-N
• Physicochemical Properties:
  Molecular Weight; 231.53; Topological Polar Surface Area; 60.4
  XlogP; N.A.; Complexity; 36.2
  Heavy Atom Count; 7; Rotatable Bond Count; 0
  Hydrogen Bond Donor Count; 0; Hydrogen Bond Acceptor Count; 4

Full List of Drug(s) Co-administrated with This DIG

33 Approved Drug(s) Co-administrated with This DIG

Drug Name	Drug ID	Indication	Formulation Name	Formulation ID
Aliskiren	DM1BV7W	Hypertension [BA00-BA04]	Aliskiren Hemifumarate eq 150mg base tablet	F23935
Alpelisib	DMEXMYK	Breast cancer [2C60-2C65]	Alpelisib 50mg tablet	F24013
Arn-509	DMT81LZ	Acute myeloid leukaemia [2A60]	Apalutamide 60 mg tablet	F23073
Cabozantinib	DMIYDT4	Thyroid cancer [2D10]	Cabozantinib S-Malate eq 80mg base capsule	F23394
Cariprazine	DMJYDVK	Bipolar disorder [6A60]	Cariprazine Hydrochloride eq 3mg base capsule	F23398
Clofazimine	DMEBOFW	Crohn disease [DD70]	Clofazimine 100mg capsule	F23118
Cysteamine	DMSYFM8	Nephropathic cystinosis [5C60]	Cysteamine Bitartrate eq 50mg base capsule	F23414
Disopyramide	DM5SYZP	Ventricular arrhythmias [BC71]	Disopyramide Phosphate eq 100mg base capsule	F23427
Elagolix sodium	DMRDUC0	Endometriosis [GA10]	Elagolix Sodium 300 mg capsule	F23728
Eltrombopag	DMOGFIX	Thrombocytopenia [3B64]	Eltrombopag Olamine eq 50mg acid tablet	F23438
Enzalutamide	DMGL19D	Prostate cancer [2C82.0]	Enzalutamide 40mg capsule	F23734
Fexofenadine	DM17ONX	Allergic rhinitis [CA08.0]	Fexofenadine Hydrochloride 180mg tablet	F23450
Hydromorphone	DMHP21E	Pain [MG30-MG3Z]	Hydromorphone 24 mg capsule	F09868
Lasmiditan	DMXLVDT	Migraine [8A80]	Lasmiditan 100 mg tablet	F23800
Lonafarnib	DMGM2Z6	Hutchinson-Gilford progeria syndrome [LD2B]	Lonafarnib 50 mg capsule	F24392
Meclofenamate sodium	DMNL98G	Arthritis [FA20]	Meclofenamate Sodium eq 50mg base capsule	F23225
Migalastat	DMFIQ2H	Fabry disease [5C56.01]	Migalastat 123 mg capsule	F23229
Moexipril	DM26E4B	Hypertension [BA00-BA04]	Moexipril Hydrochloride 7.5mg tablet	F23486
Naloxegol	DML0B41	Opioid-induced constipation [DB32.1]	Naloxegol Oxalate eq 12.5mg base tablet	F23971
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia [2A20.0]	Nilotinib Hydrochloride Monohydrate eq 50mg base capsule	F23493
Osimertinib	DMRJLAT	Non-small-cell lung cancer [2C25.Y]	Osimertinib Mesylate eq 40mg base tablet	F23977
Ozanimod	DMT6AM2	Multiple sclerosis [8A40]	Ozanimod 0.23 mg capsule	F24103
Penbutolol	DM4ES8F	Hypertension [BA00-BA04]	Penbutolol Sulfate 10mg tablet	F23353
Pentosan polysulfate	DM2HRKE	Interstitial cystitis [GC00.3]	Pentosan Polysulfate Sodium 100mg capsule	F23362
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour [2F7B]	Pexidartinib 200 mg capsule	F23256
Pimavanserin	DMR7IVC	Parkinson disease [8A00.0]	Pimavanserin Tartrate 34 mg capsule	F23515
Raltegravir	DMYURI6	Human immunodeficiency virus infection [1C62]	Raltegravir Potassium eq 400mg base tablet	F23531
Ribociclib succinate	DM9CIUW	Breast cancer [2C60-2C65]	Ribociclib Succinate 200mg tablet	F23272
Saquinavir	DMG814N	Human immunodeficiency virus infection [1C62]	Saquinavir Mesylate eq 200mg base capsule	F23546
Simeprevir	DMLUA9D	Chronic HCV-1 infection [1E51.1]	Simeprevir Sodium eq 150mg base capsule	F23355
Siponimod	DM2R86O	Multiple sclerosis [8A40]	Siponimod 0.25mg tablet	F23895
Talazoparib	DM1KS78	Breast cancer [2C60-2C65]	Talazoparib 0.25 mg capsule	F24298
Trientine	DMD2WPG	Inborn error of metabolism [5C50-5C59]	Trientine Hydrochloride 250mg capsule	F23590

2 Clinical Trial Drug(s) Co-administrated with This DIG

Drug Name	Drug ID	Indication	Formulation Name	Formulation ID
MK-4827	DMLYGH4	Ovarian cancer [2C73]	Niraparib Tosylate 100mg capsule	F23352
Selumetinib	DMC7W6R	Melanoma [2C30]	Selumetinib 10 mg capsule	F23891